P05
It is the unknown that defines our existence. We are constantly searching, not just for answers to our questions, but for new questions. We are explorers.

Latest

22
Jan
Europe’s New Health Technology Assessment Framework: Progress or Pitfall?

Europe’s New Health Technology Assessment Framework: Progress or Pitfall?

On January 12, 2025, the European Union’s Health Technology Assessment Regulation (HTAR) came into force, introducing a centralized framework
3 min read
21
Jan
The CAIA in Biotech and Pharma: A Linear Compass for a Tangled Jungle

The CAIA in Biotech and Pharma: A Linear Compass for a Tangled Jungle

The Chartered Alternative Investment Analyst (CAIA) designation positions itself as the key to unlocking the mysteries of hedge funds, private
4 min read
20
Jan
The CFA in Biotech and Pharma: Predicting the Unpredictable with the Wrong Tools

The CFA in Biotech and Pharma: Predicting the Unpredictable with the Wrong Tools

The Chartered Financial Analyst (CFA) designation once sat atop the financial world like a gold standard minted for modern markets.
4 min read
19
Jan
Fun with Funds: Exploring the XBI

Fun with Funds: Exploring the XBI

Welcome back to Fun with Funds, where we break down intriguing financial vehicles in plain English. Today’s guest is
3 min read
18
Jan
SPACs: Biotech’s Shortcut to the Big Time, or Just a Shortcut to Disaster?

SPACs: Biotech’s Shortcut to the Big Time, or Just a Shortcut to Disaster?

SPACs and Biotech: A Cautionary Tale In recent years, Special Purpose Acquisition Companies (SPACs) emerged as a popular alternative to
2 min read
17
Jan
The Davos Effect: Is It About the Debate, the Clout, or Just the View?

The Davos Effect: Is It About the Debate, the Clout, or Just the View?

Davos in January. The snow-dusted mountains, the high-altitude air of importance, and the collective hum of thousands of people all
4 min read
16
Jan
The Problem with Timid Founders: Breaking Free from the Research Mindset

The Problem with Timid Founders: Breaking Free from the Research Mindset

It is a truth universally acknowledged that a brilliant researcher in possession of a good idea is often too timid
4 min read
15
Jan
A Case Study on IP-Backed Finance: Lessons from South Korea

A Case Study on IP-Backed Finance: Lessons from South Korea

A few years ago, if someone had told me you could walk into a bank, lay a patent on the
3 min read
14
Jan
Welcome to Medicocristan: Why Mediocrity Is the Enemy of Breakthroughs

Welcome to Medicocristan: Why Mediocrity Is the Enemy of Breakthroughs

Medicocristan is a place where mediocrity reigns supreme. Its streets are orderly, its people are risk-averse, and its leaders champion
5 min read
13
Jan
Consulting: The Final Refuge of the Corporate Castaway

Consulting: The Final Refuge of the Corporate Castaway

It’s a tale as old as the severance check. A veteran employee—newly liberated from the corporate mothership—decides
4 min read